News Column

ARIAD Reports Second Quarter 2014 Financial Results and Development Progress

August 18, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) reported financial results for the second quarter of 2014, including revenue from sales of IclusigŪ (ponatinib). The Company also provided an update on corporate developments (see also ARIAD Pharmaceuticals, Inc.).

"We made steady progress in the second quarter on Iclusig sales in both the U.S. and Europe, and expect this momentum to build in the second half of the year," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "We are also focused on initiating a new randomized dose-ranging trial for Iclusig aimed at further improving the benefit/risk profile of this approved medicine and accelerating patient enrollment in the ALTA clinical trial of AP26113 in patients with ALK-positive non-small cell lung cancer." 2014 Second Quarter Financial Results Revenues Total revenue for the quarter ended June 30, 2014 was $12.1 million, which includes product revenue from sales of Iclusig and license revenue.

Keywords for this news article include: ARIAD Pharmaceuticals Inc., Investment and Finance.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters